Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

N0850000

Nimodipine

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester, Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C21H26N2O7
Numéro CAS:
66085-59-4
Poids moléculaire :
418.44
Numéro MDL:
MFCD00153848
Code UNSPSC :
41116107
ID de substance PubChem :
329818466
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

nimodipine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

COCCOC(=O)C1=C(C)NC(C)=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OC(C)C

InChI

1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3

Clé InChI

UIAGMCDKSXEBJQ-UHFFFAOYSA-N

Informations sur le gène

human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779) , NR3C2(4306)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nimodipine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

N0850010

Nimodipine impurity A, European Pharmacopoeia (EP) Reference Standard

1463870

Nimodipine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1463858

Nimodipine, United States Pharmacopeia (USP) Reference Standard

1463869

Nimodipine Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0001784

Nimodipine for peak identification, European Pharmacopoeia (EP) Reference Standard

BP651

Nimodipine, British Pharmacopoeia (BP) Reference Standard

75161

Bis(1-methylethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

BP943

Nimodipine impurity A, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

J Horn et al.
Stroke, 32(10), 2433-2438 (2001-10-06)
Based on the results of animal experiments, clinical trials were performed with nimodipine, which did not demonstrate a beneficial effect on outcome after stroke. The aim of this study was to determine whether the evidence from animal experiments with nimodipine
W Mück et al.
Die Pharmazie, 49(2-3), 130-139 (1994-02-01)
The analytical test procedures currently established for the determination of the dihydropyridine calcium antagonist nimodipine in biological fluids are presented. Method of choice which has been dominantly used in pharmacokinetic investigations and drug interaction studies is gas chromatography with electron-capture
Potential interactions between nimodipine and adrenal hormones.
R L Isaacson et al.
Annals of the New York Academy of Sciences, 765, 134-142 (1995-09-15)
Mervyn D I Vergouwen et al.
The Lancet. Neurology, 5(12), 1029-1032 (2006-11-18)
Despite several randomised controlled trials, there is still much debate whether nimodipine improves outcome in patients with traumatic subarachnoid haemorrhage. A 2003 Cochrane review reported improved outcome with nimodipine in these patients; however, because the results of Head Injury Trial
Daniele Tomassoni et al.
Clinical and experimental hypertension (New York, N.Y. : 1993), 30(8), 744-766 (2008-11-21)
Nimodipine is a 1,4-dihydropyridine-derivative Ca(2+)-channel blocker developed approximately 30 years ago. It is highly lipophilic, crosses the blood-brain barrier, and reaches brain and cerebrospinal fluid. Early treatment with nimodipine reduces the severity of neurological deficits resulting from vasospasm in subarachnoid
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique